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Medicines optimisation is a clinician-driven, person-centred ongoing process. Pharmacists and 10 
clinical pharmacologists have medicines-related expertise to deliver medication review to optimise 11 
clinical and cost effective use of medication, aligned with patient preferences, to contribute to 12 
improved health outcomes.  There is a large pharmacy workforce, directly accessible to patients, 13 
who can provide expert medicines-related care on the high street, and increasingly in General 14 
Practice and care homes settings. There are a small number of clinical pharmacologists in practice, 15 
mainly working in a hospital setting. Potential opportunities for collaboration are extensive, 16 
including local initiatives in collaborative in education, formulary/medicines management, electronic 17 
prescribing, service evaluation, research, direct clinical services as well as strategic planning through 18 
the Regional Medicines Optimisation Committees. Pharmacists and clinical pharmacologists have 19 
complementary skill sets and through acknowledging the differences in their approaches and valuing 20 
their unique skills, health services can ensure that patients are signposted to appropriate services.   21 
22 
Medicines optimisation 23 
Medicines optimisation has been variously defined by National Institute of Health and Clinical 24 
Excellence (NICE, United Kingdom) , Royal Pharmaceutical Society (RPS, Great Britain) and NHS 25 
England (1,2,3) as involving medication review to optimise clinical and cost effective use of 26 
medication, in line with patient preferences, to contribute to improved health outcomes.  It is a 27 
clinician-driven, person-centred ongoing process supporting patients in the safe, effective 28 
medicines use, to facilitate getting the most from the medicines they choose to take. The agenda is 29 
huge and requires input from different health care professions although. Medicines optimisation is 30 
the responsibility of all clinical professionals involved in improving the health of patients through 31 
medicines. Thus far, the agenda has been driven by pharmacists, clinical pharmacologists, and 32 
geriatricians as well as some general practitioners who have all led the way in both identifying 33 
patients at risk of preventable medicines-related problems and undertaking medication review to 34 
reduce this risk. This involves understanding the evidence for the effectiveness, risks and benefits of 35 
prescribing (starting) and deprescribing (stopping) medicines in relation to individual patients as well 36 
as at a population level.  This aligns with  the definition proposed by Sackett et al (4) in 1996, which 37 
describes evidence-based medicine as combining the best available research evidence and the 38 
patient’s views, goals, wishes and circumstances, using clinical judgement to agree on an 39 
appropriate way forward for medication use.  40 
Workforce 41 
The pharmacy workforce is ideally placed to support medicines optimisation in this way, using both 42 
the evidence base and person-centred skills. In 2008 approximately 70% of the workforce (table 1) 43 
was placed the community, where patients have direct access, without appointments, to 44 
increasingly expert health professionals in medicines-related care on the high street (see table 1).  45 
 46 
* Total is >100% because some respondents had more than one sector of work. 47 
The demographic is changing and pharmacists are now being deployed into new areas of practice, 48 
including General Practice and care homes. Following a successful pilot programme, 491 pharmacists 49 
began working in general practice. The General Practice Forward View (5) committed over 50 
£100million to support an extra 1,500 clinical pharmacists to work in general practice by 2020/21 51 
(6). Many of these pharmacists are already in place, running medicines optimisation clinics in general 52 
practice and in specific therapeutic areas. Additionally, there is much work being undertaken to 53 
improve medicines-related support for people in care homes, with 240 new clinical pharmacy 54 
professionals being recruited to work in care homes (7), trained through a national programme.  55 
Pharmacists in the community are directly available to patient without appointment on the high 56 
street. In addition, there are a smaller number of specialist pharmacists and Consultant Pharmacists 57 
working across primary and secondary care. A recent UK publication, known as the NHS Long term 58 
plan (8), has further developed opportunities for pharmacists to contribute to medicines 59 
optimisation. This includes increasing the number of clinical pharmacists in primary care networks 60 
supporting general practitioners and highlighting the continuing role of community pharmacists in 61 
supporting prevention.  62 
 63 
However, pharmacists are not the only health care professionals actively involved in medicines 64 
optimisation. Other such health care providers include consultants such as internists (general 65 
physicians), geriatricians and clinical pharmacologists. Given the difference in skillset between 66 
pharmacists and their medical peers (clinical pharmacologists) it is important to both professions to 67 
recognise where pharmacists skills can complement those of clinical pharmacologists, and to identify 68 
where the combined skills of others involved in medicine optimisation, such as geriatricians, can 69 
contribute to this agenda.   It is important to recognise the large difference in workforce numbers 70 
between the two professions, with 52,000 registered pharmacists in Great Britain (in 2016) and 136 71 
registered clinical pharmacologists (in 2017). In relation to the clinical pharmacology 72 
workforce, there are currently a small number of clinical pharmacologists in practice, with the Royal 73 
College of Physicians census dashboard (9) indicating 94 consultants and 42 trainees. The consultant 74 
workforce has expanded over the last 15 years from approximately 60 in 2004 to the current 94.  In 75 
relation to the 42 trainees across the UK, there are also clinical pharmacology/therapeutics  76 
academic clinical fellows and clinical lecturers in the specialty, encouraged by this speciality as a 77 
theme for the National Institute of Health Research (NIHR)   in its competition bids for academic 78 
posts. For example, in London, there are 3 lecturers and 7 academic clinical fellows, in addition to 79 
the NHS-funded clinical pharmacologist posts (10) 80 
Despite the large difference in workforce numbers, both professions are active in virtually all settings 81 
where pharmaceutical care is provided such as hospitals, nursing homes, general practice settings 82 
and communities. Medicines optimisation at the level of the individual patient is undertaken by both 83 
professions and in hospital settings, medicines optimisation committees are often chaired by a 84 
clinical pharmacologist (where available) and co-chaired by a pharmacist. As multidisciplinary,  cross-85 
sector and interface team working increases, this may result in closer working relationships between 86 
clinical pharmacologists and pharmacists, particularly in general practice, which could positively 87 
contribute to medicines-related care for the most complex patients requiring medication review.  88 
..  89 
 90 
Collaboration 91 
Given that both pharmacists and clinical pharmacologists focus on maximising the benefit and 92 
minimising harm from medication, collaboration between professions would seem a natural pairing 93 
to promote medicines optimisation in a variety of settings. However, thus far, joint working is not 94 
yet commonly found in clinical settings. A systematic review of medication review identified 95 
pharmacist-led interventions (11) and a recent evaluation discusses the potential impact of 96 
medication review in general practice (12). However there is little current evidence for the 97 
involvement of clinical pharmacologists, despite the fact that clinical pharmacologists play an 98 
essential part in medicines optimisation. Given the size of the medicines optimisation challenge,  it 99 
would be prudent to consider all suitably skilled clinical not only as contributors but also as 100 
collaborators in this work.  101 
Potential opportunities for collaboration are extensive, including initiatives in collaborative in 102 
education, formulary/medicines management, electronic prescribing, service evaluation and 103 
research as well as clinical services. One example of this is the work at University College London 104 
(UCL), University College London Hospital (UCLH) and North Central London (NCL). Future 105 
opportunities can make use of technological advances to offer opportunities for remote 106 
consultations both between professionals (pharmacists and clinical pharmacologists who are not co-107 
located). 108 
Table 2 Examples of collaborative working between pharmacists and clinical pharmacologists 109 
Education –Medical and pharmacy undergraduate students have been participating in integrated 
workshops at UCL. Pharmacists and Clinical Pharmacologist have collaborated to deliver innovative 
teaching methods, some of which become routine practice outside the university environment, for 
example, prescribing assessments and fitness to practice sessions. Clinical pharmacologists have also 
acted as Designated Medical Practitioners (DMPs) for many of the pharmacists undertaking 
independent prescribing courses. 
Formulary and Medicines Management – UCLH and NCL formulary/drug and therapeutics 
committees are joined within the NCL Sustainability and Transformation Plan (STP) footprint. They 
are run and managed collaboratively between clinical pharmacologists and pharmacists. The Chairs 
of both committees are clinical pharmacologists, and the supporting team are pharmacists. Juniors 
from both professions are involved in reviewing and presenting the evidence bases for applications.  
Prescribing technology  - The project to procure, develop, implement and electronic prescribing and 
administration technology was led by Pharmacy and supported by clinical pharmacologists who 
provided input to weekly team meetings, and the monthly project board meetings.  The project and 
rollout took four years and collaborative working has continued towards implementing a total 
electronic health record system to replace all electronic systems across the organisation. 
Audit, service evaluation and research – A Centre for Medicines Optimisation Research and 
Education (CMORE) has been established with work streams involving collaborations between 
pharmacists and clinical pharmacologists. The Board includes pharmacists and clinical 
pharmacologists, along with other academics and clinicians. 
Clinical – Clinical Pharmacologists and pharmacists are working together to explore the potential for 
a joint pharmacist/clinical pharmacologist ‘polypharmacy’ and de-prescribing clinic. While this is 
currently in the feasibility and proof-of-concept pilot phase, the demand for this is supported by 
enthusiasm from GPs it is expected that this will be a long-term venture towards shared 
responsibility for medicines optimisation. 
Personal communication: R Offord, 16th August 2018 110 
How can Regional Medicines Optimisation Committees (RMOCS) support collaboration? 111 
There are four RMOCs set up by NHS England to maximise the opportunity for collaboration in 112 
relation to all areas of medicines optimisation. The RMOCs focus on areas of healthcare where there 113 
is unwarranted variation which could benefit from sharing of best practice, such as Polypharmacy,  114 
care homes, use of Biosimilar medicines and  antimicrobial stewardship. The RMOCs aim to (13): 115 
➢ Identify best practice and evidence 116 
➢ Establish standards and metrics 117 
➢ Highlight examples of good practice 118 
➢ Support monitoring/governance 119 
The four RMOCs across England have identified areas of specific focus, with London focussing on 120 
polypharmacy. The chair and vice chair of the subgroup are a pharmacist and clinical pharmacologist 121 
and it is intended that good practice in medicines optimisation around polypharmacy will be 122 
disseminated through both professions to optimise clinical skills mix for patient benefit in this area.  123 
Challenges and enablers 124 
With any agenda as large as polypharmacy, there are challenges as well as enablers to moving this 125 
work forward. Organisational and Sustainability and Transformation Partnership (STP) priorities can 126 
promote or preclude establishment of polypharmacy reviews. The challenge of both identifying who 127 
benefits most from complex reviews and having the appropriate amount of time to undertake 128 
polypharmacy consultations is common to all health professionals involved in medicines 129 
optimisation, as dedicated time is required for complex reviews. Individual clinicians, clinical 130 
pharmacologists, geriatricians and pharmacists alike, have access to excellent tools to support 131 
medicines optimisation, such as the NHS Scotland polypharmacy tool (14), anticholinergic burden 132 
(15) and the National Health Service Business Services Authority (NHS BSA) polypharmacy metrics 133 
(16), however there are challenges to embedding the use of these tools in practice. Patients have 134 
specific views regarding polypharmacy and medication review: some may wish to reduce their 135 
medicines, some may not, and some may consider reviews as cost saving measures and reject them. 136 
For medicines optimisation consultations around polypharmacy to be effective, it will require 137 
conversations with patients to elicit their agenda: what matters to them. This needs to be combined 138 
with an easily accessible, relevant evidence base to support practitioners in using the clinical 139 
judgement to optimise medicines in person-centred way. 140 
 141 
Moving forward 142 
By identifying areas of good practice, evidence and metrics, the RMOCs can support embedding of 143 
effective medicines optimisation in the area of polypharmacy, using the skills of the most 144 
appropriate health care professionals. Both pharmacists and clinical pharmacologists can respond to 145 
the need for generalist clinicians to do this (working across all disease areas with medicines) as well 146 
as provide expert practice (expertise in use of medicines). This may be new territory for some 147 
practitioners, but both professions are aware that their traditional roles are changing and this is an 148 
opportunity not to be missed for both professionals and for patient benefit.  149 
By setting minimum standards for polypharmacy and minimum competencies for practitioners, the 150 
public will be assured that medicines optimisation consultations will be undertaken by the most 151 
suitable person for their needs.  The RMOC can work with commissioners to develop contractual 152 
levers to encourage polypharmacy activity and encourage use of validated measurable outcomes, 153 
such as NHS Business Services Authority polypharmacy metrics. The RMOC has the opportunity to be 154 
flexible about which tool or method is chosen to undertake reviews without compromising the 155 
quality or validity of the metrics. 156 
It is up to both professions to be flexible about who does the work, ensuring the competencies of 157 
whichever professional group undertakes the work. The following table illustrates how 158 
polypharmacy work could be shared according to complexity of cases and competencies of 159 
practitioners:  160 
Table 3 Complexity of medicines optimisation consultations with practitioner examples 161 
 162 
Summary 163 
Pharmacists and clinical pharmacologists have complementary skill sets. By acknowledging the 164 
differences in their approaches and valuing their unique skills, health services can ensure that 165 
patients are signposted to appropriate services. Both professions have the opportunity to work 166 
together to share  their professional experiences of patient care and medication review, learn from 167 
each other to deliver medicines optimisation consistently, widely and effectively for patient benefit.  168 
Declaration of interest 169 
No interests to declare. 170 
References 171 
1. National Institute for Health and Care Excellence. Medicines optimisation: the safe and 172 
effective us of medicines to enable the best possible outcomes. NG5 published March 2015. 173 
https://www.nice.org.uk/guidance/ng5/chapter/introduction [accessed 31 Oct 2018] 174 
2. Picton C and Wright H. Medicines Optimisation: Helping patients make the most of 175 
medicines. Royal Pharmaceutical Society. Published May 2013 176 
https://www.rpharms.com/Portals/0/RPS%20document%20library/Open%20access/Policy/177 
helping-patients-make-the-most-of-their-medicines.pdf [accessed 31 Oct 2018] 178 
3. NHS England. Medicines Optimisation. https://www.england.nhs.uk/medicines/medicines-179 
optimisation/  [accessed 31 Oct 2018] 180 
4. Sackett, David L., William MC Rosenberg, JA Muir Gray, R. Brian Haynes, and W. Scott 181 
Richardson. "Evidence based medicine: what it is and what it isn't." British Medical Journal 182 
(1996): 71-72. https://www.bmj.com/content/312/7023/71 [accessed 31 Oct 2018] 183 
5. NHS England. General practice forward view published 21 April 2016 updated 19 May 2017 184 
https://www.england.nhs.uk/publication/general-practice-forward-view-gpfv/ [accessed 31 185 
Oct 2018] 186 
6. NHS England Clinical Pharmacists in General Practice 187 
https://www.england.nhs.uk/gp/gpfv/workforce/building-the-general-practice-188 
workforce/cp-gp/ [accessed 31 Oct 2018] 189 
7. Ridge K. Pharmacists prescribing better care (blog). NHS England 20 April 2018  190 
https://www.england.nhs.uk/blog/pharmacists-prescribing-better-care/ [accessed 31 Oct 191 
2018] 192 
8. NHS Long Term Plan. NHS England published 7th January 2019 193 
https://www.longtermplan.nhs.uk/publication/nhs-long-term-plan/ [accessed 3 Feburary 194 
2019] 195 
9.  Royal College of Physicians. Focus on Physicians: 2017-18 census (UK consultants and higher 196 
speciality trainees). Royal College of Physicians 28th June 2017. 197 
https://www.rcplondon.ac.uk/projects/outputs/focus-physicians-2017-18-census-uk-198 
consultants-and-higher-specialty-trainees (accessed 25 February 2019) 199 
10. Personal communication, Professor Emma Baker, 26th February 2019  200 
11. 11 Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, Bell JS. 201 
Pharmacist-led medication review in community settings: an overview of systematic reviews. 202 
Research in Social and Administrative Pharmacy. 2017 Jul 1;13(4):661-85. 203 
https://www.ncbi.nlm.nih.gov/pubmed/27665364 204 
12. Hazen AC, de Bont AA, Leendertse AJ, Zwart DL, de Wit NJ, de Gier JJ, Bouvy ML. How Clinical 205 
Integration of Pharmacists in General Practice has Impact on Medication Therapy Management: 206 
A Theory-oriented Evaluation. International journal of integrated care. 2019 Jan 2;19(1). 207 
13. NHS England Regional Medicines Optimisation Committees. First edition April 2017 208 
https://www.england.nhs.uk/wp-content/uploads/2017/04/regional-medicines-optimisation-209 
committees-operating-model.pdf [accessed 31 Oct 2018] 210 
14. NHS Scotland  Polypharmacy Guidance Realistic Prescribing 3rrd Edition, 2018 211 
https://www.therapeutics.scot.nhs.uk/wp-content/uploads/2018/09/Polypharmacy-Guidance-212 
2018.pdf 213 
15.South London and Maudsley NHS Foundation Trust 2019 The anticholinergic effect on 214 
cognition tool http://www.medichec.com/ [accessed 3 Feburary 2019] 215 
16.National Health Service Medicines Optimisation: Polypharmacy 216 
https://www.nhsbsa.nhs.uk/epact2/dashboards-specifications/medicines-optimisation-217 
polypharmacy [accessed 3 Feburary 2019] 218 
